-
AMRI Announces Phase I Study Of Novel Drug For Obesity Treatment
7/21/2010
AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity.
-
NIH Scientists Advance Universal Flu Vaccine
7/20/2010
A universal influenza vaccine—so-called because it could potentially provide protection from all flu strains for decades—may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
-
Selvita Signs A Drug Discovery Services Contract With Rottapharm Madaus
7/20/2010
Rottapharm Madaus, the multinational pharmaceutical company, has signed a drug discovery research contract with Selvita - Poland based product and solution provider for the pharmaceutical and biotechnology industry.
-
Pfizer’s Tanezumab Trial Suspensions: A Wider Issue
7/20/2010
Having acquired rival US Wyeth in late 2009, Pfizer's R&D spend is projected to reach $9.9 billion in 2010 versus a Big Pharma average of $6.3 billion based on Datamonitor forecasts.
-
Access Pharmaceuticals Signs Agreement With Major Biotech Company To Develop Oral Formulations Of Leading Injectable Drug
7/15/2010
Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs.
-
Applied Clinical Intelligence, LLC Launches The iCommittees Solution For Clinical Endpoint Adjudication Committees And Data Safety Monitoring Committees
7/13/2010
Applied Clinical Intelligence LLC (ACI), a market leader in Clinical Endpoint Adjudication and Data Monitoring Committees (also known as DSMBs and IDMCs), recently announces iCommittees, a single, integrated solution which combines over a decade of expertise in operation and management of clinical endpoint adjudication and data safety monitoring committees with a proprietary, regulatory-compliant technology platform and a global network of scientific experts.
-
GSK And Aptuit Finalize Agreement For Aptuit To Acquire GSK’s Research Operations In Italy
7/1/2010
GlaxoSmithKline (GSK) and Aptuit, Inc. announced today that they have finalized an agreement for Aptuit to acquire operations at GSK's Medicines Research Centre in Verona, Italy.
-
Essen BioScience And Nycomed Announce Ion Channel Drug Discovery Collaboration
7/1/2010
Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services – and Nycomed – a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics
-
CBio Announces Clinical Trial Milestone
7/1/2010
Australian drug development company CBio Limited (ASX: CBZ) today announced the achievement of a recruitment milestone in its clinical trial of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA).
-
NORD Calls For Statement Of Policy On Orphan Drug Development
7/1/2010
Noting that only about 200 of the nearly 7,000 diseases classified as rare currently have treatments, the National Organization for Rare Disorders (NORD) today called for a Food and Drug Administration (FDA) statement of policy on regulation of therapies for rare disorders.
